{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:46:11Z","timestamp":1771461971942,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019214","name":"l\u00e9ka\u0159sk\u00e1 fakulta Univerzity Karlovy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013088","name":"Jiangsu Provincial Qinglan Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017702","name":"Innovation and Entrepreneurship Talent Project of Lanzhou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115711","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:11:27Z","timestamp":1691547087000},"page":"115711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"259","author":[{"given":"Tizhi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengteng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-1195","authenticated-orcid":false,"given":"Jinlei","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115711_bib1","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115711_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejmech.2023.115711_bib3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115711_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","article-title":"CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia","volume":"37","author":"Rahaman","year":"2019","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115711_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibitio","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2023.115711_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","article-title":"New strategies to treat AML: novel insights into AML survival pathways and combination therapies","volume":"35","author":"Nair","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2023.115711_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115711_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"22","author":"Vervoort","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2023.115711_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/jcb.26293","article-title":"A key player in cancer and other diseases","volume":"119","author":"Franco","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2023.115711_bib10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s10637-019-00868-3","article-title":"Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models","volume":"38","author":"Wang","year":"2020","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2023.115711_bib11","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21856","article-title":"Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline","volume":"42","author":"Bhurta","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115711_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2023.115711_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejmech.2019.01.003","article-title":"Recent development of CDK inhibitors: an overview of CDK\/inhibitor co-crystal structures","volume":"15","author":"Cheng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115711_bib15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1021\/acs.biochem.2c00609","article-title":"Addressing transcriptional dysregulation in cancer through CDK9 inhibition","volume":"62","author":"Toure","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.115711_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/21541264.2018.1523668","article-title":"A signaling hub for transcriptional control","volume":"10","author":"Bacon","year":"2019","journal-title":"Transcription"},{"key":"10.1016\/j.ejmech.2023.115711_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543776.2023.2208747","article-title":"A patent review of selective CDK9 inhibitors in treating cancer","volume":"33","author":"Wu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115711_bib18","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an Update","volume":"63","author":"Wu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib19","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/cancers14051113","article-title":"An orally bioavailable and highly efficacious inhibitor of CDK9\/FLT3 for the treatment of acute myeloid leukemia","volume":"14","author":"Anshabo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2023.115711_bib20","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114461","article-title":"Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies","volume":"238","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib22","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.1c01148","article-title":"Rational design and development of novel CDK9 inhibitors for the treatment of acute myeloid leukemia","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/14756366.2021.1890726","article-title":"Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy","volume":"36","author":"Alsfouk","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/13543784.2016.1169273","article-title":"Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia","volume":"25","author":"Wiernik","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115711_bib25","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cmdc.201700447","article-title":"Identification of atuveciclib (BAY1143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of cancer","volume":"12","author":"L\u00fccking","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115711_bib26","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for the better: discovery of the highly potent and selective CDK9 Inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer","volume":"64","author":"L\u00fccking","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib27","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","article-title":"First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy","volume":"28","author":"Diamond","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115711_bib28","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2022-167203","article-title":"Safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of the cyclin-dependent kinase-9 (CDK9) inhibitor AZD4573 in relapsed\/refractory hematological malignancies: a phase 1 first-in-human study","volume":"140","author":"Brummendorf","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115711_bib29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejmech.2019.06.024","article-title":"Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity","volume":"178","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115711_bib30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ejmech.2018.09.025","article-title":"Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423006785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:02:33Z","timestamp":1759330953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423006785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"alternative-id":["S0223523423006785"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115711","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115711"}}